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Methods and Results. We prospectively and serially measured the radionuclide left ventricular ejection fraction and the RSA amplitude in 34 cancer patients receiving up to nine monthly bolus treatments with doxorubicin hydrochloride (60 mg/m2). Of the eight patients who ultimately developed symptomatic doxorubicin-induced congestive heart failure, seven (87.5%) demonstrated a significant decline in RSA amplitude; five of 26 subjects without clinical symptoms of cardiotoxicity (19.2%) showed a similar RSA amplitude decline. On average, significant RSA amplitude decline occurred 3 months before the last planned doxorubicin dose in patients destined to develop clinical congestive heart failure.
Conclusion. Overall, RSA amplitude abnormality proved to be a more specific predictor of clinically significant congestive heart failure than did serial resting radionuclide ejection fractions. (Circulation 1991;84:697-707) D oxorubicin hydrochloride is one of the most frequently used and broadly active chemotherapeutic agents available for the treatment of common cancers, having been administered to more than five million cancer patients in the United States alone.1-7 Unfortunately, the prolonged survival of successfully treated cancer patients has revealed delayed cardiotoxicity to be a major and dose-limiting side effect of doxorubicin therapy. This toxicity, or fear of inducing it, often limits the total amount of doxorubicin given, even when the drug is primarily responsible for control or potential cure of the patient's cancer. When cumulative doses of intermittent bolus doxorubicin exceed 550 mg/m2, doxorubicin-induced cardiac failure occurs in 5-10% of patients; of this number, one fourth succumb to the syndrome, one half require lifelong cardiac treatment, and one fourth recover satisfactorily.8-10 Anticancer drug dose intensity can be a critical factor in determining whether patients will respond to chemotherapy, how well their cancers will be controlled, and whether they will be cured.'1 Because concern for delayed congestive heart failure (CHF) very frequently limits the dose intensity of doxorubicin therapy, oncologists are continuously faced with the difficult task of determining when it is safe for a patient to receive further doxorubicin therapy without undue risk of major delayed cardiac dysfunction. This risk-benefit assessment could benefit from a simple, reliable, noninvasive test with some predictive value.
The respiratory sinus arrhythmia (RSA) is a physiological phenomenon that diminishes predictably with advancing age (Figure 1 ).12 This observation suggested to us that quantitatively assessed RSA might provide a reliable measure of myocardial health and function and that changes in this physiological phenomenon might reliably predict the development of clinically significant doxorubicin cardiotoxicity. This paper describes the effect of doxorubicin administration on the amount of rhythmic heart rate change during normal breathing (RSA amplitude). Serial RSA amplitude quantification (expressed as percentage expected for age) is compared FIGURE 1. Age-related decline in amplitude of respiratory sinus arrhythmia (RSA) observed in 326 clinically healthy individuals ranging from 7 to 80 years of age. Points represent mean±SEM for n=11, 5-year subgroups. On average, the amplitude of the RSA declines 10% per decade between the second and ninth decades of life. with serial resting radionuclide angiography (currently the most widely used screening test) as predictors for the development of clinically significant symptomatic doxorubicin-induced CHF.
Materials and Methods

Intertest Variability
Twenty-five presumably healthy individuals aged 20 to 82 years, taking no medications, were tested serially before and after venipuncture, in the morning of the same day at 7 AM and 9 AM, respectively. Interindividual and intertest variabilities were then quantified and contrasted by two-way analysis of variance. The heart rate, amplitude, and phasing of the RSA showed relative stability. The degree of intraindividual variability in these parameters was always much smaller than the amount of interindividual variability (Table  1) . In this and other populations similarly studied, the mean heart rate, amplitude, and phasing of the RSA showed relative intraindividual intertest stability. The amount of heart rate and RSA amplitude variability due to age class or between individuals was always far 
Gender
The ratio imbalance in the number of men and women who develop CHF, obvious in Table 3 , is at least in part explained by the sex dependence of tumor type and, therefore, outcome in these patients. Ovarian cancer is more successfully treated with chemotherapy than is transitional-cell bladder cancer, whereas bladder cancer is predominantly a disease of older men. In fact, 80% of the bladder cancer patients in this series are male and because these individuals more frequently failed therapy, they sometimes received somewhat lower cumulative doxorubicin doses. Men received a mean of 474±+31 mg/M2, whereas women received an average of 516±15 mg/M2 (not statistically different at the 5% level). Therefore, by virtue of diagnosis and average doxorubicin exposure, males were at lower risk for the development of doxorubicin-induced CHF. No single-sex predominance has been reported for doxorubicin-induced CHF to date. The confounding aspect of sex-dependent diagnosis and doxorubicin dose allows no such conclusion to be drawn from our data.
Definition of Clinical Doxorubicin-Induced CHF Doxorubicin-induced CHF was determined by the presence of the classic syndrome of relatively sudden onset of new CHF in the absence of other causes and was confirmed by symptom history and physical find- Quantification of the RSA All RSA measurements were made using a computer-based pulse monitor during voluntary cardiorespiratory synchronization. The principal features of this device and the method for its use have been summarized elsewhere.12 Briefly, the pulse monitor measures the relation of respiration and heart rate by collecting instantaneous heart-rate data through a noninvasive earclip (as calculated from the pulsepulse intervals) while simultaneously measuring inhalation and exhalation with a thermal sensor in a respiratory mouthpiece. Symbols on a computer screen tell the subject when to inhale and exhale, thereby synchronizing the subject's cardiac and respiratory cycles so that an inhalation occurs during two heartbeats and an exhalation during three heartbeats. Respiratory volume is fixed at the patient's usual tidal volume. The software then fits the instantaneous heart rates to the best-fitting cosine curve by least-squares analysis14 with a period length equal to the respiratory cycle, each of which comprises six measured pulses. The amplitude (one half the peaktrough difference) of this modeled curve is the datum used to quantify the RSA of each subject.
All data in this report were obtained using the ratio of two beats for inspiration followed by three beats for expiration, but any desired ratio may be studied in this way. The beat-to-beat interval translated to instantaneous heart rate is the experimental datum. These data were sorted and stored according to their exact position in the five-beat cycle and then analyzed. The first pulse corresponds to the interval between the first and second beats of the inspiration phase of the respiratory cycle.
Biological functions are rhythmic within many time frames. The RSA represents an ultradian or highfrequency biological rhythm. All data are analyzed and reported independent of time in terms of the arbitrarily preselected and standardized period length of five heartbeats. The data are expressed as average instantaneous heart rate during each of the five beats of this five-beat rhythm. If the average pulse during 1 minute is 75 beats/min, 15 continuous pulse cycles of a five-beat rhythm are evaluated in that minute. Single cosinor analysis was used to investigate each series of pulse data for five-beat rhythmicity. This analysis involves a least-squares regression fit of a cosine curve to the data points. The fitted curve describes the shape of this rhythm by providing the mean pulse value, the amplitude, and the timing of the peak with their respective 95% confidence intervals. The population mean cosinor analysis was used to investigate whether the rhythm characteristics of individual data series were consistent. 15 Heart-rate data were collected for at least 10 respiratory cycles per test (about 1 minute), with two tests obtained for each subject at each testing session. Classic analyses of variance were used in addition to cosinor analysis to discern individual and group differences in mean RSA amplitude. A statistically significant rhythm is described by 1) a good leastsquares curve fit that successfully rejects the zeroamplitude hypothesis (p<0.05) and 2) pulse mean differences throughout the respiratory cycle (beats [1] [2] [3] [4] [5] [6] where EF is ejection fraction, CD is counts at end diastole, and Cs is counts at end systole. The study was visually assessed by a nuclear medicine physician to ensure that the edge of the ventricle was accurately detected, that the background region of interest was appropriately placed, that the patient was adequately positioned, that electrocardiographic gat-ing was successful, and that wall motion was evaluated for focal abnormalities.
Left ventricular ejection fractions were obtained directly from the nuclear medicine films in each subject's hospital file. Ejection fraction data were expressed in two ways: 1) as an absolute ejection fraction and 2) as a percentage of initial ejection fraction (taken before the onset of doxorubicin treatment). A positive result for cardiotoxicity was considered by five routine cutoff techniques: ejection fraction of less than 55%, less than 50%, or less than 45%; or a fall in ejection fraction of 10% or greater or 15% or greater. The University of Minnesota Hospital's Nuclear Medicine Division routinely considers a fall of 5% or greater as being a significant decline and an ejection fraction value of less than 50% as being abnormal. In addition to these numerical values, a subjective assessment of the quality of ventricular wall motion was also reported.
Radionuclide ventriculography was routinely performed before the first, fifth, and ninth treatments. Additional tests were also obtained at later stages of doxorubicin treatment when clinically indicated. Adequate data (at least three serial studies) for three asymptomatic subjects were not available, however, so these individuals (who did have serial RSA determinations) are not included for the evaluation of ejection fraction. A total of 70 ejection fractions were recorded for individuals who did not develop significant CHF (an average of 3.0 serial measurements per subject, n =23), whereas 31 such tests were done in patients who ultimately developed significant CHF (an average of 3.9 serial measurements per subject, n=8).
Results
Effects of Doxorubicin on the RSA Amplitude Table 3 shows that eight subjects developed classic symptomatic doxorubicin-induced CHF, whereas Figure 2) . relating doxorubicin dose with RSA amplitude expressed as percent expected for age is also significant for the heart failure group (r=-0.41, p<0.008). This function declines about 4.1% per doxorubicin course, so that after the nine planned treatments, on average, the corrected-for-age RSA has diminished by nearly half The values from members of the asymptomatic group show no such trend (r=-0.02, p=NS). Each point represents the mean +SEM for the number of subjects tested in each group before that particular monthly treatment.
demonstrates that the decline in amplitude in the heart-damaged group was premonitory, occurring several months before the diagnosis of clinical doxorubicin-induced CHF could be made and, more importantly, several months before the last planned monthly doxorubicin dose. fraction below 50% was considered predictive of or suspicious for CHF, five of the eight symptomatic patients were detected. Only four of the eight had ejection fractions below 45% or showed a net decline of more than 10% throughout therapy. In addition, Table 4 shows that regardless of commonly chosen cutoff points for ejection fraction results, RSA amplitude proved comparatively more capable of discerning those individuals with drug-induced CHF from those without. The behavior of the mean value of the ejection fraction was also analyzed by two-way analysis of variance techniques as a function of the doxorubicin course number and revealed no difference between the heart-damaged and asymptomatic groups, with mean values of both groups falling similarly (see Figure 3 ). Linear regression analyses of the behavior of absolute ejection fraction over time (doxorubicin course) clearly demonstrate longitudinal declines with very similar slopes in both groups (clinically significant cardiotoxicity: r= -0.39, p<0.04, slope of 1.7% per course; no clinical cardiotoxicity: r= -0.51, p<0.001, slope of 1.8% per course). A similar effect of treatment is seen when ejection fraction is expressed as a percentage of the initial ejection fraction (clinically significant cardiotoxicity: r=-0.41, p<0.05, slope of 2.6% per course; no clinical cardiotoxicity: r=-0.52, p<0.001, slope of 2.9% per course).
Interpretation of the above description of the longitudinal behavior of the RSA and the ventricular ejection fraction of groups of eight and 26 cancer patients who ultimately did or did not develop doxorubicin-induced congestive cardiomyopathy, respectively, must be qualified by the fact that the analyses of prospectively obtained data have been performed retrospectively. The strength of this approach ensured that changes in the RSA did not affect how the patients were treated. The disadvantage of this approach is that because the data were not being used for clinical decision making, the test was not performed as frequently as might have been optimal. Interindividual variability of the test in health has been shown to be minimal; in disease, however, less is known. Although behavior of the group data indicates that RSA falloff may be premonitory, this U .
in ejection fraction determination could be diminished by double gating the ejection fraction determination to the electrocardiographic signal and, concurrently, to the breathing cycle, which is responsible for substantial reproducible rhythmic changes in cardiac volume. Perhaps if ejection fraction determinations from similar points within the respiratory cycle were averaged separately, rather than averaged across all points in respiration, the breathing phase qualified test result would have less variability and ultimately prove more useful. In addition, the average difference in cardiac volume and/or ejection fraction across the respiratory cycle may itself yield interesting dynamic information. The RSA has long been known to diminish with advancing age. The mechanisms involved in this decrease, however, have not been clearly established. Much of the difficulty in understanding the agerelated diminution of the RSA is due to the complex and still poorly understood physiological basis for the RSA. A sizable body of research has accumulated that attributes the RSA to changes in autonomic nervous impulses reaching the heart. For instance, in anesthetized dogs, sympathetic and vagal nervous impulses to the heart have been found to fluctuate in synchrony with phrenic nerve impulses and diaphragmatic movement.32 Enhanced vagal tone has also been found to increase the RSA.33 On the other hand, studies of patients with diabetic autonomic neuropathy and after recent heart transplantation demonstrate that the RSA can persist in the denervated heart.12 These results point to the existence of an additional intrathoracic mechanism, possibly in accordance with Bainbridge's34 1920 explanation that the RSA is caused at least in part by the effect of intrathoracic pressure changes on the venous return to the heart and the response of an intracardiac reflex to these changes.34 Because in our current study patients did not demonstrate other evidence of autonomic neuropathy, changes in RSA seem to reflect the direct effect of doxorubicin on the heart muscle itself. The precise mechanism of how doxorubicin causes a decrease in the RSA remains to be established. Even cursory inspection of the stiffened myocardium of patients dying from this therapeutic complication, however, would lead one to conclude that this less compliant tissue would not behave similarly to normal myocardium when presented with small, regular, breathing-induced changes in venous return. In other studies, we have found that patients with normal autonomic function and cardiac abnormalities primarily characterized by decreased ventricular compliance, including concentric cardiac hypertrophy and hypertensive cardiomyopathy, also have markedly diminished RSAs.
Although cardiac biopsy is considered by many to be the gold standard for documentation of the presence and extent of doxorubicin-induced myocardial lesion, the procedure is expensive and invasive. For noninvasive measurement of doxorubicin-induced cardiotoxicity, radionuclide ventriculography has become the most commonly used screening test. Serial endomyocardial biopsies, proven to be reliable and useful, would have allowed us to compare the accuracy of the RSA and ejection fraction results in predicting subsequent heart failure. Such biopsies were not done because they are invasive and because few are routinely done outside centers with pathologists and cardiologists who have specific research interests in drug-induced cardiotoxicity. Although we were not able to perform exercise radionuclide ventriculography on our subjects, resting radionuclide ventriculography, the test most commonly used by medical oncologists to evaluate a patient's risk for development of doxorubicin-induced CHF, was less effective than RSA amplitude determination in discriminating between patients with and without early preclinical progressive cardiomyopathy. This simple, noninvasive, 1-minute test seems to provide some useful screening information relevant to the common clinical conundrum posed by high-dose-intensity doxorubicin treatment, and it deserves careful further study.
